Shunqiang Li

Associate Professor

Washington University in St. Louis
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (49)

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial in regulating cell-cycle progression and cancer development. Targeting CDK4/6 has shown considerable promise in treating various cancers, including breast cancer. Despite significant therapeutic efficacy, resistance to CDK4/6 inhibitors (CDK4/6i), such as palbociclib, remains a substantial hurdle in clinical practice. Using a coculture system, cytokine array, and quantitative high-throughput combinatorial screening, we discovered a mechanism by which the Runt-related transcription factor (RUNX) 1–platelet-derived growth factor (PDGF)-BB axis regulates palbociclib resistance in breast cancer cells. Specifically, RUNX1 functioned as a transcription factor to drive expression of PDGFB , leading to resistance to palbociclib by enhancing the Akt pathway and suppressing senescence. Furthermore, in resistant cells, RUNX1 was O-GlcNAcylated at serine 252 by O-GlcNAc transferase, resulting in the stabilization of RUNX1 by preventing ubiquitin-mediated degradation. Inhibition of the RUNX1–PDGF-BB axis by specific inhibitors overcame palbociclib resistance both in vitro and in vivo . Notably, the RUNX1–PDGF-BB axis was upregulated in resistant patient-derived xenograft lines and in patients with breast cancer following treatment with CDK4/6i. These findings not only unveil O-GlcNAcylation–mediated activation of a RUNX1–PDGF-BB pathway as a driver of palbociclib resistance but also provide clinical evidence supporting the repurposing of FDA-approved PDGFR inhibitors as a therapeutic strategy to treat patients with CDK4/6i-resistant breast cancer. Significance: RUNX1-PDGF-BB signaling drives resistance to CDK4/6 inhibition in breast cancer, providing the foundation to develop approaches to target the RUNX1-PDGF-BB axis to overcome CDK4/6 inhibitor resistance in breast cancer patients.

Year:

2025

In metastatic breast cancer, HER2 -activating mutations frequently co-occur with mutations in PIK3CA , TP53 , or CDH1 . Of these co-occurring mutations, HER2 and PIK3CA are the most commonly comutated gene pair, with approximately 40% of HER2 -mutated breast cancers also having activating mutations in PIK3CA . To study the effects of co-occurring HER2 and PIK3CA mutations, we generated genetically engineered mice with the HER2 V777L ; PIK3CA H1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids. HP breast cancers showed accelerated tumor formation in vivo and increased invasion and migration in in vitro assays. HP breast cancer cells were resistant to the pan-HER tyrosine kinase inhibitor, neratinib, but were effectively treated with neratinib plus the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan. Proteomic and RNA-seq analysis of HP breast cancers identified increased gene expression of cyclin D1 and p21WAF1/Cip1 and changes in cell-cycle markers. Combining neratinib with CDK4/6 inhibitors was another effective strategy for treating HP breast cancers, with neratinib plus palbociclib showing a statistically significant reduction in development of mouse HP tumors as compared to either drug alone. The efficacy of both the neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations was validated using a human breast cancer patient-derived xenograft with very similar HER2 and PIK3CA mutations to the HP mice. Further, these two drug combinations effectively treated spontaneous lung metastasis in syngeneic mice transplanted with HP breast cancer organoids. This study provides valuable preclinical data to support the ongoing phase 1 clinical trials of these drug combinations in breast cancer. Significance: In HER2 -mutated breast cancer, PIK3CA mutation activates p21–CDK4/6–cyclin D1 signaling to drive resistance to HER2-targeted therapies, which can be overcome using CDK4/6 inhibitors.

Year:

2025

In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in the PIK3CA, TP53, or E-cadherin genes. Of these co-occurring mutations, HER2 and PIK3CA mutations are the most prevalent gene pair, with approximately 40% of HER2 mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we bred genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids. HP breast cancers show accelerated tumor formation in vivo and increased invasion and migration in in vitro assays. HP breast cancers have resistance to the pan-HER tyrosine kinase inhibitor, neratinib, but are effectively treated by neratinib plus trastuzumab deruxtecan. Proteomic and RNA-Seq analysis of HP breast cancers showed increased gene expression of Cyclin D1 and p21WAF1/Cip1 and changes in cell cycle markers. Combining neratinib with CDK4/6 inhibitors was another effective strategy for HP breast cancers with neratinib plus palbociclib showing a statistically significant reduction in mouse HP tumors as compared to either drug alone. We validated both the neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations using a human breast cancer patient-derived xenograft with very similar HER2 and PIK3CA mutations. Further, these two drug combinations effectively treated spontaneous lung metastasis in syngeneic mice transplanted with HP breast cancer organoids. Both of these drug combinations are being tested in phase 1 clinical trials and this study provides valuable preclinical evidence for them.

Year:

2024

Transcriptionally active ESR1 gene fusions (ESR1-TAF) are a potent cause of breast cancer endocrine therapy (ET) resistance. ESR1-TAFs are not directly druggable because the C-terminal estrogen/anti-estrogen binding domain is replaced with translocated in-frame partner gene sequences that confer constitutive transactivation. To discover alternative treatments, a mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) was deployed to identify druggable kinases that are upregulated by diverse ESR1-TAFs. Subsequent explorations of drug sensitivity validated RET kinase as a common therapeutic vulnerability despite remarkable ESR1-TAF C-terminal sequence and structural diversity. Organoids and xenografts from a pan-ET resistant patient-derived xenograft (PDX) model that harbors the ESR1-e6>YAP1 TAF were concordantly inhibited by the selective RET inhibitor pralsetinib to a similar extent as the CDK4/6 inhibitor palbociclib. Together, these findings provide preclinical rationale for clinical evaluation of RET inhibition for the treatment of ESR1-TAF-driven ET resistant breast cancer.

Year:

2024

Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.

Year:

2024

Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.

Year:

2024

Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed on PDX samples, which could be harnessed for computational analysis. Prior studies of large clinical H&E image repositories have shown that deep learning analysis can identify intercellular and morphologic signals correlated with disease phenotype and therapeutic response. In this study, we developed an extensive, pan-cancer repository of >1,000 PDX and paired parental tumor H&E images. These images, curated from the PDX Development and Trial Centers Research Network Consortium, had a range of associated genomic and transcriptomic data, clinical metadata, pathologic assessments of cell composition, and, in several cases, detailed pathologic annotations of neoplastic, stromal, and necrotic regions. The amenability of these images to deep learning was highlighted through three applications: (i) development of a classifier for neoplastic, stromal, and necrotic regions; (ii) development of a predictor of xenograft-transplant lymphoproliferative disorder; and (iii) application of a published predictor of microsatellite instability. Together, this PDX Development and Trial Centers Research Network image repository provides a valuable resource for controlled digital pathology analysis, both for the evaluation of technical issues and for the development of computational image–based methods that make clinical predictions based on PDX treatment studies. Significance: A pan-cancer repository of >1,000 patient-derived xenograft hematoxylin and eosin–stained images will facilitate cancer biology investigations through histopathologic analysis and contributes important model system data that expand existing human histology repositories.

Year:

2024

Tumor growth response to eribulin and copanlisib, either alone or in combination in WHIM29 and WHIM34. A, Tumor volume changes over time compared with that of day 1 after receiving either vehicle, eribulin (0.3 mg/kg i.p. on day 1 of each week × 4, except that 0.1 mg/kg eribulin was administered for the first two doses in WHIM29), copanlisib (10 mg/kg i.v. on days 2 and 3 each week × 4), or the combination of copanlisib and eribulin at the same dosing ( n = 5 per group). B, Kaplan–Meier survival duration (days) of tumor-bearing mice after receiving treatments indicated in A. *, P P

Year:

2024

Tumor growth response to eribulin and copanlisib, either alone or in combination in WHIM29 and WHIM34. A, Tumor volume changes over time compared with that of day 1 after receiving either vehicle, eribulin (0.3 mg/kg i.p. on day 1 of each week × 4, except that 0.1 mg/kg eribulin was administered for the first two doses in WHIM29), copanlisib (10 mg/kg i.v. on days 2 and 3 each week × 4), or the combination of copanlisib and eribulin at the same dosing ( n = 5 per group). B, Kaplan–Meier survival duration (days) of tumor-bearing mice after receiving treatments indicated in A. *, P P

Year:

2024

PI3K pathway alterations of selected TNBC PDX models. A, Molecular characteristics of the eight TNBC PDX models included in this study, including mutation status of candidate genes based on whole exome sequencing, breast cancer intrinsic subtype and TNBC subtype derived from gene expression profiling, and PI3K pathway signaling activity indicated by levels of AKT phosphorylation and PTEN by RPPA analysis for each model. B, Representative pictures of PTEN IHC, demonstrating loss of PTEN expression in four of the eight PDX models. The number at the right lower corner of each IHC picture refers to the WHIM ID of the PDX model analyzed. Note the positive PTEN staining of the stromal cells, which serves as an internal control.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (53)

Matthew H Bailey

Assistant Professor

Brigham Young University

UNITED STATES
View details

Yirui Sun

Washington University in St. Louis

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Cornelius von Morze

-

UNITED STATES
View details

Gerburg Wulf

Harvard University

UNITED STATES
View details

Sherri Davies

Senior Scientist

Washington University in St. Louis

UNITED STATES
View details

Ron Bose

Washington University School of Medicine

UNITED STATES
View details

Michael Nickels

Associate Professor

University of Washington Medical Center

UNITED STATES
View details

Meenakshi Anurag

Assistant Professor (Tenure track)

Baylor College of Medicine

UNITED STATES
View details

Dennis Hallahan

Professor-Joint Appointment

Washington University in St. Louis

UNITED STATES
View details

Zhuqing Li

Assistant Research Professor

George Washington University

UNITED STATES
View details

Buck E. Rogers

Professor

Washington University School of Medicine

UNITED STATES
View details

Peter Robinson

Professor for Medical Computer Science

The Jackson Laboratory for Genomic Medicine

UNITED STATES
View details

Jeffrey Chuang

Jackson Laboratory

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Junfeng Ma

Georgetown University Medical Center

UNITED STATES
View details

Anna Malovannaya

Baylor College of Medicine

UNITED STATES
View details

Shidan Wang

-

UNITED STATES
View details

Edward Seto

The George Washington University School of Medicine and Health SCiences

UNITED STATES
View details

Yongjian Liu

Washington University in St. Louis

UNITED STATES
View details

Matthew J. Ellis

Director

Baylor College of Medicine

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

Kooresh Shoghi

Professor

Washington University in St. Louis

UNITED STATES
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Ian Hagemann

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Bryan Welm

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

Jason M. Held

Washington University School of Medicine

UNITED STATES
View details

Samuel Achilefu

Chair/Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Charles Foulds

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Luis G Carvajal‐Carmona

Professor

University of California, Davis

UNITED STATES
View details

Matthew Hall

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Mashl

Washington University in St. Louis

UNITED STATES
View details

Chong-xian Pan

Professor

university of california davis medical center

UNITED STATES
View details

Carol Bult

Professor and Knowlton Family Chair

Jackson Laboratory

UNITED STATES
View details

Wenge Zhu

Professor

The George Washington University School of Medicine and Health SCiences

UNITED STATES
View details

Shuyan Zhou

George Washington University

UNITED STATES
View details

Salma Kaochar

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Li Ding

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Chunyan Hou

Georgetown University

UNITED STATES
View details

Abhay Singh

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

YANJUN GAO

George Washington University

UNITED STATES
View details

Michael Lewis

Baylor College of Medicine

UNITED STATES
View details

jingqin luo

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Soner Koc

GlaxoSmithKline Research and Development

UNITED STATES
View details

Vaishali Kapoor

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Guanghua Xiao

-

UNITED STATES
View details

Yang Xie

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details